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Background: The intraaortic balloon pump (IABP) is the most commonly used mechanical circulatory support
for patients with acute coronary syndromes and cardiogenic shock. Nevertheless, IABP-related complications
are still frequent and associated with a poor prognosis.
Hypothesis: To prospectively assess the incidence and predictors of complications in patients treated with
IABP.
Methods: A total of 481 patients treated with IABP were prospectively enrolled in our registry (the Florence
Registry). At multivariable logistic regression analysis the following variables were independent predictors for
complications (when adjusted for age >75 years, eGFR and time length of IABP support): use of inotropes (OR
2.450, P < 0.017), nadir platelet count (1000/μL step; OR 0.990, P < 0.001), admission lactate (OR 1.175,
P = 0.003). Nadir platelet count showed a negative correlation with length of time of IABP implantation
(r −0.31; P < 0.001). A nadir platelet count cutoff value of less than 120,000 was identified using a receiver
operating characteristic (ROC) curve for the development of complications (area under the curve [AUC] 0.70;
P < 0.001).
Results: Complications were observed in the 13.1%, among whom 33 of 63 showed major bleeding. The
incidence of complications was higher in patients aged >75 years (P = 0.015) and in those who had an IABP
implanted for more than 24 hours (P = 0.001). Patients with complications showed an in Intensive Cardiac
Care Unit (ICCU) mortality higher than patients who did not (44.4% vs 17.2%, P < 0.001).
Conclusions: In consecutive patients treated with IABP support, the degree of hemodynamic impairment
and the decrease in platelet count were independent predictors of complications, whose development was
associated with higher in-ICCU mortality.
Introduction
The intraaortic balloon pump (IABP) is currently the most
commonly used mechanical circulatory support for patients
with acute coronary syndromes (ACS) and cardiogenic
shock (CS).
According to guidelines,1 IABP implantation is indicated
(class I C) in patients with CS and in those with me-
chanical complications of acute myocardial infarction.
However, in the clinical practice, IABP is often implanted
also in hemodynamically stable patients at high risk of
complications during percutaneous coronary intervention
(PCI) or coronary artery bypass graft (CABG).2–6
In the last decade, IABP technology has made signif-
icant progress (sheathless insertion7 technique, different
balloon diameters, optic fiber IABP) to reduce complications
and improve patient support. Nevertheless, IABP-related
complications are still frequent and associated with a poor
prognosis.6,8,9
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The present investigation was therefore aimed at
prospectively assessing the incidence and predictors of
complications in 481 patients treated with IABP implantation
and consecutively admitted to our Intensive Cardiac Care
Unit (ICCU) (the Florence Registry).
Methods
Study Population
From January 1, 2004 to December 31, 2009, 481 patients
underwent intraaortic counterpulsation in our ICCU and
were prospectively enrolled in the Florence Registry.
All patient data, including demographics, baseline char-
acteristics and admission diagnosis, type and severity of
heart disease, data regarding IABP management, including
concomitant medications, which were left to the discretion of
the treating physician, were stored in a dedicated database.
According to our policy, testing for heparin-induced
thrombocytopenia (HIT) was performed on clinical sus-
picion and whenever thrombocytopenia (a platelet count
<150, 000) or a 50% or greater reduction in platelet count
from baseline developed.
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Major bleeding was defined according to the ACUITY
criteria as follows10: intracranial or intraocular bleeding;
access site hemorrhage requiring intervention, 5-cm-
diameter hematoma, clinically overt blood loss with
hemoglobin decrease 3 g/dL, any hemoglobin decrease
4 g/dL, or blood-product transfusion
Definitions
IABP Positioning: The balloon catheter was inserted
according to the Seldinger technique via the left or right
femoral artery either in the catheterization laboratory or
in the ICCU. Sheathless or non-sheathless insertion was
decided according to the operator’s discretion. Balloon
diameters ranged from 7 to 8 F according to the patient’s
height. Our ICCU policy is to remove the device as soon as
possible, immediately after hemodynamics is restored or at
the end of high risk procedures.6
Large Ischemic Risk Area: The large ischemic risk area
(LIRA)6 was defined as ‘‘ejection fraction less than 40% (at
angiography or transthoracic echocardiogram) associated
with proximal occlusion of left descending anterior coronary
artery and or not with coexisting critical lesions in other
coronary arteries.’’
High-Risk Patients: Patients were defined as ‘‘high risk’’
if 1 or more of the following criteria were present: left
ventricular ejection fraction (LVEF) <40%, Killip class 3,
persistent malignant ventricular arrhythmias, acute mitral
regurgitation and severe coronary artery disease (left main
stem or 3-vessel or vein graft disease).6,11
Informed consent was obtained from all patients.
Statistical Methods
Patient data were collected and analyzed using SPSS 13.0
statistical software (SPSS Inc., Chicago, IL). Continuous
data were tested for normality with the Kolmogorov-Smirnov
test; variables that were non-normally distributed were log-
transformed in order to meet normality. These variables
were expressed as mean ± standard deviation (SD) and
analyzed by means of Student t test. Length of IABP
treatment has been reported as median and 25th to 75th
percentile; comparisons were made with Mann-Whitney U
test. Categorical data were reported as frequencies and
percentages and analyzed by means of chi-square (or
Fisher’s exact test when needed). To examine adjusted
predictors of complications, variables that were considered
clinically relevant and that showed an univariate relationship
with outcome were entered into a logistic regression model.
Variables for inclusions were carefully chosen, given the
number of events available, to avoid overfitting of the
final model. Goodness-of-fit (Hosmer-Lemeshow) test was
reported. The correlation between platelets (PTL) minimum
and time length of IABP implantation was investigated by
means of a linear regression analysis (Pearson’s r value). A
receiver operating characteristic (ROC) curve was plotted
to identify a cutoff of nadir PTL count with respect to
complications. A 2-tailedP value less than 5% was considered
statistically significant.
Results
Baseline data of the study group are shown in Table 1. The
mean age of patients in the study was 69.6 ± 12.3 years;
Table 1. Baseline Demographics and Clinical Characteristics of the 481
Patients Included in the Study
Mean ± SD or Frequency (%)
Age (y) 69.6 ± 12.3
Gender (M/F) 333/148 (69.2/30.8)
BSA (m2) 1.85 ± 0.19
Familiar history 121 (25.2)
Smoke habit (ever smokers) 251 (52.2)
Obesity 92 (19.1)
Hypertension 249 (51.8)
Dyslipidemia 153 (31.8)
Diabetes 108 (22.5)
Peripheral arteriopathy 17 (3.4)
Neurologic impairment 16 (3.2)
Previous myocardial infarction 120 (24.9)
Previous PCI 102 (21.2)
Previous cardiac surgery 12 (2.5)
Chronic renal disease 42 (8.7)
Chronic obstructive pulmonary disease 44 (9.1)
Neoplasm 36 (7.5)
Abbreviations: BSA, body surface area; PCI, percutaneous coronary
intervention; SD, standard deviation.
69.2% were men. Hypertension was detectable in 51.8%
(n = 249), dyslipidemia in 31.8% (n = 153), and diabetes
mellitus in 22.5% (n = 108). About one-fourth of patients
(24.9%) showed prior myocardial infarction and the 21.2% of
patients had a prior PCI.
Indications to IABP implantation are depicted in Table 2.
In our population, IABP was positioned for ST-elevation
myocardial infarction (STEMI) in most cases (70.1%).
Among STEMI patients, IABP was implanted in patients
in Killip class I/II (31.4%) because of LIRA and in 35.3% of
patients because of cardiogenic shock. In unstable angina
or non-ST-elevation myocardial infarction (NSTEMI) the
most common indications were severe coronary artery
disease in high-risk patients (29.2%), followed by persistent
hypotension (17.5%), cardiogenic shock (15.8%), and
periprocedural complications (10.8%). IABP was positioned
in 10 patients (8.3%) with CABG indication for presurgery
stabilization.
Devices and therapies used during hospitalization are
showed in Table 3. In the majority of patients (66.1%,
n = 318) IABP was the only device, while in the remaining
(33.9%) it was associated with other devices. The device
most frequently associated with IABP was mechanical
ventilation (44.7%; invasive: 26.0%; noninvasive 18.7%). The
continuous venovenous renal replacement therapy was used
in the 14.8% (n = 71) of patients. Unfractionated heparin
was used in 95.8% of patients. The majority of patients
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Table 2. IABP Indications
Diagnosis IABP Indication Frequency (%)
STEMI (n = 337 [70.1%]) Large ischemic risk area 106 (31.4)
Cardiogenic shock 119 (35.3)
Hypotension 45 (13.4)
Sudden death/VF 15 (4.4)
In the catheter laboratory 4
Outside the catheter
laboratory
11
PCI failure 14 (4.2)
Acute pulmonary edema 14 (4.2)
Mechanical complications 19 (5.6)
Mitral regurgitation 9
VSD 10
Periprocedural complications 2 (0.6)
Preoperative support 3 (0.9)
UA/NSTEMI (n = 120
[24.9%])
Severe coronary artery disease
in high risk patients
35 (29.2)
Hypotension 21 (17.5)
Cardiogenic shock 19 (15.8)
Periprocedural complications 13 (10.8)
Acute pulmonary edema 10 (8.3)
Preoperative support 10 (8.3)
Sudden death/VF 8 (6.6)
In the catheter laboratory 4
Outside the catheter
laboratory
4
Mechanical complications 2 (1.7%)
Mitral regurgitation 2
VSD 0
PCI failure 2 (1.7%)
CHD with CABG indication
(n = 9 [1.9%])
Preoperative support 9 (100%)
Other (n = 15 [3.1%]) Election procedure 1 (6.7%)
Cardiogenic shock 14 (93.3%)
Abbreviations: CABG, coronary artery bypass graft; CHD, coronary heart
disease; IABP, intraaortic balloon pump; NSTEMI, non-ST elevation
myocardial infarction; PCI, percutaneous coronary intervention; STEMI,
ST elevation myocardial infarction; UA, unstable angina; VF, ventricular
fibrillation; VSD, ventricular septal defect.
received dual antiplatelet therapy: acetylsalicylic acid
(90.0%) and clopidogrel (81.7%). Therapy with glycoprotein
IIb/IIIa inhibitors was administered in 55.1% of cases.
Inotropic agents (epinephrine, norepinephrine, dopamine,
Table 3. Devices and Drugs
Frequency (%)
Devices
IABP only 318 (66.1)
IABP + 1 other device 70 (14.6)
IABP + 2 other devices 64 (13.3)
IABP + 3 other devices 29 (6.0)
IABP 481 (100)
IOT 124 (26.0)
C-PAP 90 (18.7)
CVVHDF 71 (14.8)
Drugs
Unfractionated heparin 461 (95.8)
Acetylsalicylic acid 433 (90.0)
Clopidogrel 393 (81.7)
Glycoprotein IIb/IIIa inhibitors 265 (55.1)
Inotropes 214 (44.5)
Ticlopidin 15 (3.1)
Abbreviatons: C-PAP, continuous positive airways pressure ventilation;
CVVHDF, continuous venovenous hemodiafiltration; IABP, intraaortic
balloon pump; IOT, orotracheal intubation.
Table 4. IABP Complications
Frequency (%)
Complications (total) 63/481 (13.1)
Strictly related to IABP
Severe bleeding 33 (52.4)
Nonspecific site (acute anemia) 16 (58.5)
Bleeding at the insertion site 13 (39.4)
Retroperitoneal hematoma 4 (12.1)
Limb ischemia 10 (15.9)
Systemic embolization (renal/mesenteric infarct) 5 (7.9)
Pseudoaneurysm of femoral artery 3 (4.8)
Not strictly related to IABP
Gastrointestinal and urinary bleeding 12 (19.0)
IABP, intraaortic balloon pump.
and dobutamine) were used in 44.5% of patients, all with
cardiogenic shock.
Complications
Data regarding complications are shown in Table 4. In our
series, complications were observed in 13.1% (63/481) of
patients. Thirty-three patients (out of 63, 52.4%) showed
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Figure 1. Incidence of IABP complications. Abbreviation: IABP, intraaortic
balloon pump.
major bleeding, among whom one-half exhibited unknown
bleeding site while bleeding at the insertion site occurred
in 13 patients. Four patients developed a retroperitoneal
hematoma (1 patient died). Limb ischemia complicated
hospital course in 10 patients, all reversed by IABP removal.
The less frequent adverse events in our series were the
occurrence of renal infarct (2 patients) and mesenteric
infarct (3 patients) caused by systemic embolization. Three
patients developed pseudoaneurysm of femoral artery at the
IABP insertion site.
Twelve patients (19.0%) developed complications not
strictly related to IABP implantation, represented by severe
gastrointestinal or urinary bleeding.
As depicted in Figure 1, the incidence of complications
was higher in patients aged >75 years (P = 0.015) and in
those who had a IABP implanted for more than 24 hours
(P = 0.001) whereas no difference was observed between
males and females in the incidence of complications. In the
overall population, median time length of IABP treatment
was 36 hours (25th–75th percentile: 22–50 hours).
Predictors of Complications: Unadjusted predictors of
complications at univariable logistic regression analysis are
depicted in Figure 2.
At multivariable logistic regression analysis the following
variables resulted independent predictors for complications
(when adjusted for age >75 years, estimated glomerular
filtration rate [eGFR], and time length of IABP support):
inotropes drug use (yes vs no) (OR 2.450; 95% CI,
1.168–5.035; P = 0.017); nadir platelet count (1000/μ
l step) (OR 0.990; 95% CI, 0.985–0.996; P < 0.001);
Figure 2. Unadjusted predictors of complications at univariable logistic
regression analysis. Abbreviations: EF, ejection fraction; eGFR, estimated
glomerular filtration rate; IABP, intraaortic balloon pump.
Admission lactate (1 mmol per l step) (OR 1.175; 95%
CI, 1.058–1.306; P = 0.003). Hosmer and Lemeshow
goodness-of-fit test χ2 = 9.61, P = 0.294.
At linear regression analysis, nadir PTL count showed a
negative correlation with time length of IABP implantation
(r −0.31; P < 0.001). A cutoff value of less than 120,000
for nadir PTL count was identified on a ROC curve for
the development of complications (area under the curve
[AUC] 0.70; 95% CI, 0.63–0.68; P < 0.001); sensitivity
65%, specificity 72%; predictive value of positive test 27%,
predictive value of negative test 92%. In facts, patients
with nadir PTL less than 120,000/μL showed a higher
complication rate (26.7 vs 7.3%, P < 0.001), with an OR
4.617 (95% CI, 2.645–8.064). A median time length of IABP
treatment of 45.5 hours was identified on a ROC curve for
the development of nadir platelet count (AUC 0.68; 95%
CI, 0.63–0.73; P < 0.001); sensitivity 63%, specificity 65%;
predictive value of positive test 46%, predictive value of
negative test 78%.
In our series, 2 patients developed HIT and were treated
with lepirudin; 1 patient died because of retroperitoneal
hematoma.
Mortality
In our population, 100 patients died (100/481; 20.8%). Among
patients who died, IABP was implanted due to cardiogenic
shock or persistent hypotension in 75 patients (75%); cardiac
arrest in 8 patients (8%); periprocedural complications
of PCI in 6 patients (6%); mechanical complication of
acute myocardial infarction in 4 patients (4%); LIRA in
4 patients (4%); acute pulmonary edema in 2 patients
(2%); and bridge to CABG in 1 patient (1%). Patients
who developed complications showed an in-ICCU mortality
significantly higher than patients who did not (44.4% vs
17.2%; P < 0.001).
Discussion
The main finding of our investigation, which was performed
in a large series of patients treated with IABP, is that
the degree of hemodynamic impairment (as indicated
by inotropes use and admission lactate) and the nadir
platelet count are independent predictors of complications,
whose development was associated with a higher in-ICCU
mortality.
The development of thrombocytopenia after IABP implan-
tation has been investigated in previous studies,8,12–15 with
conflicting results. In 1978, McCabe et al12 reported that
thrombocytopenia, though detectable in all patients, was not
related to the development of complications. Vonderheide
et al13 observed, in a prospective study of 58 patients treated
with IABP, that the use of this device led to steady and pre-
dictable decrease in platelet count, which recovered rapidly
if the balloon pump was removed or slowly if the device
remained in place. Bream-Rouwenhorst et al,14 in a retro-
spective cohort study involving 107 patients undergoing
IABP, reported that the development of thrombocytopenia
occurred in 58% of patients and was not related to the
use of antiplatelet therapy. Recently, Roy et al8 assessed
the incidence and predictors of thrombocytopenia in 252
consecutive patients treated with IABP and documented
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that in-hospital death and major bleedings were higher
in patients who developed thrombocytopenia. However,
since at multivariable analysis thrombocytopenia was not
an independent predictor either of in-hospital death or
major bleeding, the authors concluded that IABP-associated
thrombocytopenia should not necessarily prompt discontin-
uation of IABP support or important adjunctive medications.
Similarly, in a recent small observational study,15 thrombo-
cytopenia, though a common finding, was not associated
with serious adverse consequences.
Since the development of IABP in 1962,16 the incidence
rate and the type of complications have deeply changed over
time. Whereas in 1978, Mc Cabe et al12 reported an incidence
rate of 23% and complications were mainly represented by
vascular damage induced by insertion, in the Benchmark
Registry17 (enrolling 16,909 patients), complication rate
dropped to 2.6% and major bleeding and limb ischemia
were the most frequent complications.
Whereas progress in IABP technology can account for the
significant reduction in vascular complications, nowadays
major bleedings remain the most frequent complications
in patients treated with IABP support and still represent a
clinical and therapeutic challenge.
In our study, performed in a larger series of patients,
we confirmed that major bleedings are the most frequent
complications and documented that the nadir platelet count
is an independent predictor of complications and that
thrombocytopenia can be related to mechanical factors
because it is inversely correlated to the duration of IABP
support.
In our series, unfractionated heparin was administered to
nearly all patients (95.8%) and heparin-related immunogenic
and nonimmunogenic causes of thrombocytopenia, when
suspected, have been excluded by means of testing for HIT.
The inverse relation between thrombocytopenia and IABP
duration strongly suggests that the reduction in PTL can be
related to mechanical factors.
Recent reports18,19 strongly suggest a relation between
baseline or acquired thrombocytopenia and outcomes
(ischemic and hemorrhagic complications) was suggested
in patients undergoing PCI for acute coronary syndrome.
In an analysis of the HORIZONS-AMI trial, baseline throm-
bocytopenia in STEMI patients was associated with early
adverse events, related to both ischemia and bleeding.18 In
the ACUITY trial, acquired thrombocytopenia, occurring in
approximately 1 in 14 patients, was strongly associated with
hemorrhagic and ischemic complications.19
Conclusion
In conclusion, in consecutive patients treated with IABP
support, the development of complications is associated
with higher in-ICCU mortality. The degree of hemodynamic
impairment (as indicated by inotropic use and admission
lactate) and the nadir platelet count (whose development is
related to the duration of IABP support) were independent
predictors of complications.
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